Nucleophosmin (NPM1), CCAAT/enhancer-binding protein alpha (CEBPA), FMS like tyrosine kinase 3- internal tandem duplication (FLT3-ITD) and proto-oncogene receptor tyrosine kinase (KIT) are the most common mutations in AML patients, dictating the development of the leukemia and rearranging them into different prognostic groups (Welch et al., 2012; Yohe, 2015; Figure 3). The gene discussed is CEBPA; the disease is leukemia.